Skip to content Skip to sidebar Skip to footer
Home / what tree does the drug company bristol-myers want to harvest?

what tree does the drug company bristol-myers want to harvest?

Post a Comment

American pharmaceutical company

Bristol Myers Squibb
Formerly Bristol-Myers Visitor (1933–1989)
Bristol-Myers Squibb Company (1989–2020)
Type Public company

Traded as
  • NYSE: BMY
  • South&P 100 component
  • S&P 500 component
Industry Pharmaceuticals
Founded 1887; 135 years ago  (1887)
Founders
  • William McLaren Bristol
  • John Ripley Myers
  • Eastward. R. Squibb
Headquarters 430 East 29th Street
New York Urban center, New York, U.s.a.

Key people

 Giovanni Caforio, Thousand.D.
(Chairman & CEO)
David Elkins
(CFO)
Revenue Increase US$42.518 billion (2020)[i]

Operating income

 Increase U.s.$30.745 billion (2020)[ane]

Cyberspace income

 Negative increase United states$viii.995 billion (2020)[one]
Full assets Increase The states$129.44 billion (2019)[2]
Total equity Increase United states of america$59.lxx billion (2019) [2]

Number of employees

 Increase thirty,000 (2019)[two]
Website BMS.com

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York Metropolis. BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.South. corporations. Every bit of September 2020, information technology had total revenue of $39.three billion.[iii]

Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.

BMS'southward primary R&D sites are located in Lawrence, New Bailiwick of jersey (formerly Squibb, near Princeton), Top, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey, Redwood Urban center, California, and Boudry in Switzerland, with other sites in Devens and Cambridge, Massachusetts, East Syracuse, New York, Braine-l'Alleud, Kingdom of belgium, Tokyo, Japan, Bangalore, Republic of india, and Wirral, United Kingdom.[four] [5] BMS previously had an R&D site in Wallingford, Connecticut (formerly Bristol-Myers).[6]

History [edit]

Squibb [edit]

E.R. Squibb & Son facility in Long Island City, New York, in 1948

The Squibb corporation was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York.[7] [8] Squibb was known equally an advocate of quality control and high purity standards early on within the pharmaceutical industry.[9] He went on to cocky-publish an culling to the U.S. Pharmacopeia titled Squibb's Ephemeris of Materia Medica, later on failing to convince the American Medical Association to comprise higher purity standards.[10] Materia Medica, Squibb products, and Edward Squibb's stance on the fundamentals of chemist's shop are establish in many medical papers of the late 1800s.[xi] [12] [13] [xiv] The American Journal of Pharmacy published more than ane hundred papers of Squibb's research surrounding the manufacture.[15]

The sons of Edward Squibb sold the company to Lowell Thousand. Palmer and Theodore Weicker in 1905, who incorporated the company. Around this time, the Squibb logo was developed, which represented the company's products of "uniformity, purity, efficacy, and reliability based on inquiry."[xvi]

Squibb Corporation served every bit a major supplier of medical goods to the Marriage Army during the American Civil War, providing portable medical kits containing morphine, surgical anesthetics, and quinine for the treatment of malaria (which was endemic in most of the Eastern Us at that time).[17] [18]

In 1944, Squibb opened the world'south largest penicillin institute in New Brunswick, New Jersey.[19]

Bristol-Myers [edit]

In 1887, Hamilton College graduates William McLaren Bristol and John Ripley Myers purchased the Clinton Pharmaceutical company of Clinton, New York.[20] In May 1898, they decided to rename it Bristol, Myers and Company.[20] Following Myers' death in 1899, Bristol changed the proper noun to the Bristol-Myers Corporation.[20] During the 1890s, the company introduced its commencement nationally recognized product Sal Hepatica, a laxative mineral salt, followed by Ipana toothpaste in 1901.[21] [22] Other divisions were Clairol (hair colors and haircare) and Drackett (household products such as Windex and Drano).[23]

In 1943, Bristol-Myers acquired Cheplin Biological Laboratories, a producer of acidophilus milk in E Syracuse, New York,[24] and converted the institute to produce penicillin for the Globe War Ii Allied forces.[25] After the war, the company renamed the plant Bristol Laboratories in 1945 and entered the civilian antibiotics marketplace, where information technology faced competition from Squibb.[21] Penicillin product at the East Syracuse constitute ended in 2005, when information technology became less expensive to produce overseas.[26] [27] As of 2010, the facility was used for the manufacturing process development and product of other biologic medicines for clinical trials and commercial utilise.[28] [29]

Merger [edit]

In 1989, Bristol-Myers and Squibb merged and became Bristol-Myers Squibb.[thirty]

In 1999, then-U.S. President Neb Clinton awarded Bristol-Myers Squibb the National Medal of Technology, the nation's highest recognition for technological achievement, "for extending, and enhancing human life through innovative pharmaceutical research and development and for redefining the scientific discipline of clinical written report through groundbreaking and hugely circuitous clinical trials that are recognized models in the industry."[31]

2000 to 2010 [edit]

Bristol-Myers Squibb logo from 1996 to 2020

The company has a number of facilities in New Bailiwick of jersey; this one is on the edge between West Windsor and Princeton.

In 2002, the company was involved in a lawsuit of illegally maintaining a monopoly on Taxol, its cancer treatment, and it was again sued for the antitrust lawsuit 5 years afterward, which toll the visitor $125 million for settlement.[32]

Also in 2002, Bristol-Myers Squibb was involved in an accounting scandal that resulted in a significant restatement of revenues from 1999 to 2001.[33] The restatement was the result of an improper booking of sales related to "channel stuffing" as the practice of offer excess inventory to customers to create college sales numbers.[33] The visitor has since settled with the Us Section of Justice and Securities and Exchange Commission, agreeing to pay $150 million, while neither admitting nor denying guilt.[34]

On October 24, 2002, Bristol-Myers Squibb Co. restated earnings downward for parts of 2000 and 2001, while revising this year's earnings upward because of its massive inventory backlog imbroglio that spurred two government investigations.[35] On March 15, 2004, Bristol-Myers Squibb Co. adjusted upward its fourth-quarter and total-year 2003 results after reversing an before determination about how to deal with bookkeeping errors made in prior years.[36] As part of a deferred prosecution agreement, the visitor was placed nether the oversight of a monitor appointed by the U.S. attorney in west Jersey. In add-on, the quondam head of the Pharma group, Richard Lane, and the ex-CFO, Fred Schiff, were indicted for federal securities violations.[37]

Plavix 2007-04-19.jpg

In July 2006, an investigation of the company was fabricated public, and the FBI raided the company's corporate offices.[38] The investigation centered on the distribution of Plavix and charges of bunco.[38] [39] On September 12, 2006, the monitor, quondam Federal Judge Frederick B. Lacey, urged the company to remove then-CEO Peter Dolan over the Plavix dispute. Later that twenty-four hours, BMS appear that Dolan would indeed step down.[forty]

The deferred prosecution understanding expired in June 2007 and the Section of Justice did not accept whatever farther legal activity against the company for matters covered by the DPA. Under CEO Jim Cornelius, who was CEO following Dolan until May 2010, all executives involved in the "channel-stuffing" and generic competition scandals have since left the company.

In 2009, the visitor began a major restructuring focusing on the pharmaceutical business and biologic products, along with productivity initiatives and cost-cut and streamlining business operations through a multiyear program of on-going layoffs. This was part of a business strategy launched in 2007 to transform the company from a big, diversified pharmaceutical company to a specialty biopharma company, which besides included the closure of half of their manufacturing facilities.[41] : 19 As some other cost-cutting measure out, Bristol-Myers Squibb also reduced wellness-care subsidies for retirees and plans to freeze their pension plan at the stop of 2009.[42] [43]

BMS is a Fortune 500 Company (#114 in 2010 list). Newsweek'due south 2009 Green Ranking recognized Bristol-Myers Squibb as 8th among 500 of the largest United states corporations. Likewise, BMS was included in the 2009 Dow Jones Sustainability North America Index of leading sustainability-driven companies.

Lamberto Andreotti was named CEO in 2010; he had previously served equally "president and COO responsible for all pharmaceutical operations worldwide."[44]

2010 onward [edit]

Bristol-Myers Squibb facility in Wirral, England

In 2010, Lou Schmukler joined Bristol-Myers Squibb equally the president of global product development and design.[41] [45] Schmukler led the team that completed the company's strategic transformation to a specialty biopharmaceutical company that had begun in 2007.[41] As of 2011, the visitor had a dozen manufacturing facilities and half dozen product evolution sites.[41]

Citing major developments and a market capitalization of Usa$87 billion and stock appreciation of 61.four%, Bristol-Myers Squibb was ranked equally the all-time drug company of 2013 by Forbes mag.[46]

In December 2014, the company received FDA approval for the use of the PD-one inhibitor nivolumab (Opdivo) in treating patients whose pare cancer cannot be removed or have non responded to previous drug therapies.[47] In February 2015, the company initiated a inquiry partnership with Rigel Pharmaceuticals which could generate more than $339 million. In March, the company obtained an exclusive opportunity to both licence and commercialise PROSTVAC, Bavarian Nordic's phase III prostate-specific antigen targeting cancer immunotherapy. Bavarian Nordic would receive an upfront payment of $lx million and incremental payments upward to $230 1000000, if the overall survival of test patients exceeds that seen in Phase II tests. Bavarian could also receive milestone payments of between $110 meg and $495 million, dependent on regulatory authorization, and these payments accept the potential to total upward to $975 1000000.[48]

In May 2015, Dr. Giovanni Caforio became CEO of the visitor;[49] Caforio was formerly the visitor's COO and succeeded Andreotti upon his retirement.[44] Andreotti subsequently succeeded James Cornelius as executive chairman upon his retirement.[44]

In late February 2017, The Wall Street Periodical and Fortune, among others, reported that activist investor Carl Icahn had taken a stake in the company, signaling a potential future takeover[50] [51] from the likes of Gilead Sciences.[52]

In April 2018, the company reported net income of $1.5 billion, or 91 cents per share, for the start quarter of the year, thanks to the increased sales of their cancer drug Opdivo.[53]

Corporate acquisitions and divestments as Bristol Myers Squibb [edit]

Buspar.jpg

In August 2009, during a major restructuring activity, BMS acquired the biotechnology business firm Medarex equally role of the company'south "Cord of Pearls" strategy of alliances, partnerships, and acquisitions.[54] [55] In November 2009, Bristol Myers Squibb announced that it was "splitting off" Mead Johnson Nutrition by offering BMY shareholders the opportunity to commutation their stock for shares in Mead Johnson.[56] Co-ordinate to Bristol Myers Squibb, this move was expected to further sharpen the company's focus on biopharmaceuticals.[56]

In October 2010, the company acquired ZymoGenetics, securing an existing product, as well equally pipeline assets in hepatitis C, cancer, and other therapeutic areas.

Bristol Myers Squibb agreed to pay around $ii.5 billion in cash to buy Inhibitex Inc. in attempt to compete with Gilead/Pharmasset to produce hepatitis C drugs. The settlement will be finished in 2 months for its Inhibitex's shareholders acceptance of 126% premium cost of its cost over the previous 20 trading days ended on January 6.[57] On June 29, BMS extended its portfolio of diabetes treatments when information technology agreed to buy Amylin Pharmaceuticals for around Us$5.3 billion in cash and pay US$1.seven billion to Eli Lilly to cover Amylin'due south debt and its outstanding collaboration-related obligations.[58] AstraZeneca, which already collaborated on several diabetes treatments with BMS, agreed to pay US$3.iv billion in cash for the correct to go along development of Amylin's products.[58] Two years subsequently, the company divested Amylin to AstraZeneca.[41] : 19

In April 2014, BMS announced its acquisition of iPierian for up to $725 million.[59]

In Feb 2015, the company caused Flexus Biosciences for $1.25 billion. As function of this deal, BMS volition gain full rights to Flexus' lead modest molecule IDO1-inhibitor, F001287.[threescore] In Nov, the visitor caused the cardiovascular affliction drug developer Cardioxyl for up to $2.075 billion. The deal strengthens the BMS' critical pipelines with the phase II candidate for acute decompensated heart failure, CXL-1427.[61]

In March 2016, the company announced information technology would acquire Padlock Therapeutics for upward to $600 million.[62] In early July, the company announced it would acquire Cormorant Pharmaceuticals for $520 million, boosting BMS' oncology offering through Cormorants monoclonal antibody targeted against interleukin-8.[63]

In August 2017 the company acquired IFM Therapeutics for $300 million upfront, with contingency payments of $1.01 billion due on certain milestones – allowing BMS to better compete against Merck & Co's cancer rival treatment, Keytruda.[64]

In early January 2019, the company announced information technology would acquire Celgene (NASDAQ:CELG) for $74 billion ($95 billion including debt[65]), in a deal that would become the largest pharmaceutical-visitor acquisition ever.[66] The Celgene conquering aimed to be a refresher to the company's pipeline, helping to overcome from declining sales of Opdivo relative to competitor Keytruda.[67] Under the terms of the deal, Celgene shareholders would receive i BMS share as well every bit $fifty in greenbacks for each Celgene share held, valuing Celgene at $102.43 a share; representing a 54% premium to the previous days closing toll.[66] Investor opposition to this acquisition, leading into an April 12 shareholder vote, appeared when BMS's 2d-largest investor, Wellington Management, voiced its opposition, followed by investor Starboard Value.[67] In April 2019 BMS announced that 75% of its shareholders voted to approve the pending merger with Celgene. Transaction to close in the third quarter of 2019, subject field to regulatory approvals.[68] Newly issued BMS shares and CVRs will embark trading on the New York Stock Exchange, with the CVRs trading nether the symbol 'BMYRT'.[69]

The strategic divestment of the company'south consumer wellness business, UPSA, to Taisho completed in 2019.[seventy] UPSA focused production delivery on France and the rest of Europe. Every bit early equally 2005, the company had divested individual consumer products,[71] [72] and its US- and Canada-focused consumer products business concern.[73]

In Baronial, the Amgen announced it would acquire the Otezla drug programme from Celgene for $thirteen.four billion, every bit role of Celgene and BMS's merger deal.[74] [75]

In February 2020, BMS and partner Biomotiv launched a new company called Anteros Pharmaceuticals, which focuses on creating inflammation and fibrosis medicines.[76] In August, the business announced it would acquire Forbius and its TGF-beta 1 & TGF-beta 3 inhibitors.[77] In October, BMS announced information technology would acquire cardiology company MyoKardia for $thirteen.1 billion ($225 per share) gaining control of mavacamten, a cardiovascular drug for obstructive hypertrophic cardiomyopathy (HCM), and the development of ii key treatments: danicamtiv (MYK-491) and MYK-224.[78]

List of mergers and acquisitions [edit]

The following is an illustration of the company's major mergers and acquisitions and historical predecessors:

  • Bristol-Myers Squibb (Formed past the merger of Squibb Corporation (Est 1858) and Bristol-Myers (Est 1887))
    • Adnexus Therapeutics
    • ConvaTec
    • Kosan Biosciences
    • Medarex (Acq 2009)
    • ZymoGenetics (Acq 2010)
    • Amira Pharmaceuticals
    • Inhibitex Inc (Acq 2012)
    • Amylin Pharmaceuticals (Acq 2012 jointly with AstraZeneca)
    • iPierian (Acq 2014)
    • Flexus Biosciences (Acq 2015)
    • Cardioxyl (Acq 2015)
    • Padlock Therapeutics (Acq 2016)
    • Cormorant Pharmaceuticals (Acq 2016)
    • IFM Therapeutics (Acq 2017)
    • Celgene (Acq 2019)
      • Signal Pharmaceuticals, Inc (Acq 2000)
      • Anthrogenesis (Acq 2002)
      • Pharmion Corporation (Acq 2008)
      • Gloucester Pharmaceuticals (Acq 2009)
      • Abraxis BioScience Inc (Acq 2010)
      • Avila Therapeutics, Inc (Acq 2012)
      • Quanticel (Acq 2015)
      • Receptos (Acq 2015)
      • EngMab AG (Acq 2016)
      • Delinia (Acq 2017)
      • Bear upon Biomedicines (Acq 2018)
      • Juno Therapeutics (Acq 2018)
        • AbVitro (Acq 2016)
        • RedoxTherapies (Acq 2016)
    • Forbius (Acq 2020)
    • MyoKardia (Acq 2020)

Finances [edit]

For the financial year 2017, Bristol Myers Squibb reported earnings of US$1.007 billion, with an annual revenue of US$twenty.776 billion, an increase of vi.9% over the previous fiscal cycle. Bristol-Myers Squibb's shares traded at over $55 per share, and its marketplace capitalization was valued at over Us$81.6 billion in October 2018.[79] In 2018, 85% of the company's revenues came from but five products.[lxxx] In 2018, Bristol-Myers Squibb spent 36% of its total revenue on R&D expenses.[81] Bristol-Myers Squibb ranked 145th on the Fortune 500 listing of the largest United States corporations by revenue in 2018.[82]

Yr Acquirement
in bil. USD$ 		Net income
in bil. USD$ 		Full assets
in bil. USD$ 		Toll per share
in USD$ 		Employees
2005 eighteen.lx 3.00 28.14 14.60
2006 16.xx one.59 25.58 15.24
2007 15.62 ii.17 25.93 18.98
2008 17.72 five.25 29.49 14.95
2009 xviii.81 10.60 31.00 15.90
2010 19.48 3.09 31.08 19.76
2011 21.24 3.70 32.97 23.41
2012 17.62 ane.96 35.xc 28.04
2013 16.39 two.56 38.60 38.39 28,000
2014 15.88 2.00 33.75 47.03 25,000
2015 16.56 1.57 31.75 59.63 25,000
2016 nineteen.43 four,457 33.71 59.73 25,000
2017 xx.78 ane.00 33.55 55.88 23,700
2018 22.56 4.92 34.99 51.98 23,300
2019 26.fifteen eighteen.06 129.44 52.23 30,000

Carbon footprint [edit]

Bristol Myers Squibb reported Total CO2e emissions (Direct + Indirect) for the twelve months ending 31 December 2020 at 278 Kt (-6 /-2.1% y-o-y).[83] The visitor aims to become cyberspace neutral carbon by 2040.[84]

Bristol Myers Squibb's almanac Full CO2e Emissions - Location-Based Scope 1 + Telescopic ii (in kilotonnes)[85]
December 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020
328 323 316 284 278

Pharmaceuticals [edit]

Hydrea (hydroxycarbamide)

The following is a list of key pharmaceutical products:[86]

Out of production [edit]

  • Sal Hepatica
  • Ipana

Divested brands [edit]

(Quondam Bristol-Myers brands, now divested)

  • Bufferin
  • Excedrin[71]
  • Ban Deodorant
  • Vitalis (hair tonic)[72] [ self-published source ]
  • Ammens (medicated powder)
  • Concluding Net (pilus spray)
  • Comtrex (cold relief capsules)
  • Keri (lotion)[73] [ self-published source ]

Products under evolution [edit]

The following is a selective list of investigational products under development, as of 2015:[89]

  • Beclabuvir (BMS-791325) – phase III
  • BMS-906024 – stage I
  • BMS-955176 – phase II
  • Brivanib alaninate (BMS-582664) – evolution terminated
  • Elotuzumab (BMS-901608) – phase III
  • Fostemsavir (BMS-663068) – approved in the United States in July 2020
  • Lirilumab (BMS-986015)
  • Lulizumab pegol (BMS-931699) – phase II

Scandals [edit]

Bristol-Myers Squibb, Johns Hopkins University and the Rockefeller Foundation are currently the subject field of a $one billion lawsuit from Guatemala for "roles in a 1940s U.Due south. regime experiment that infected hundreds of Guatemalans with syphilis".[90] A previous adjust against the United States authorities was dismissed in 2011 for the Guatemala syphilis experiments when a judge determined that the U.Due south. government could not be held liable for deportment committed exterior of the U.S.[91]

See also [edit]

  • List of biotech and pharmaceutical companies in the New York metropolitan surface area

Notes and references [edit]

  1. ^ a b c "Bristol Myers Squibb 2020 Total-Twelvemonth Financial Results" (PDF). s21.q4cdn.com. Bristol Myers Squibb. 5 February 2021. Archived (PDF) from the original on 15 February 2021. Retrieved 5 February 2021.
  2. ^ a b c "Bristol Myers Squibb 2019 Annual Report" (PDF). s21.q4cdn.com. Bristol Myers Squibb. 23 February 2020. Archived (PDF) from the original on 14 April 2021. Retrieved 28 August 2020.
  3. ^ "Bristol-Myers Squibb – Contact Us". xviii March 2020. Archived from the original on 27 April 2020. Retrieved 18 March 2020.
  4. ^ "Bristol-Myers Squibb and Biocon'south Syngene open new R&D Facility at Biocon Park" (Press release). Archived from the original on 29 September 2012. Retrieved 16 May 2012.
  5. ^ "Worldwide Inquiry and Development Facilities – Bristol Myers Squibb". www.bms.com. Archived from the original on 7 June 2020. Retrieved vii June 2020.
  6. ^ "Bristol-Myers Squibb to lay off 149 every bit Wallingford, Connecticut, site nears closure". Fiercepharma.com. Archived from the original on four Feb 2019. Retrieved 3 February 2019.
  7. ^ Gray, Christopher (30 Baronial 2012). "Still in Manner, a Century Later". The New York Times. ISSN 0362-4331. Archived from the original on 20 March 2020. Retrieved 20 March 2020.
  8. ^ Kumar, B. (xiv November 2012). Mega Mergers and Acquisitions: Instance Studies from Cardinal Industries. Springer. ISBN978-1-137-00590-8. Archived from the original on 14 April 2021. Retrieved 15 October 2020.
  9. ^ The National Druggist. 1905. Archived from the original on 14 Apr 2021. Retrieved 15 Oct 2020.
  10. ^ "E. R. Squibb | American pharmacist". Encyclopedia Britannica. Archived from the original on 20 March 2020. Retrieved 20 March 2020.
  11. ^ Hollopeter, W.C. (8 January 1885). "Inverse Type of Temperature in Typhoid Fever, with a Written report of Two Cases — Temperature Peculiarities in Epidemics, with a Written report of Seven Cases in One Family". Boston Medical and Surgical Journal. 112: 28–32. doi:x.1056/NEJM188308301090903. Archived from the original on 19 Oct 2015. Retrieved 25 November 2014. The writer noticed (in December, 1882) the important fact that when common or Nihon camphor and crystallized carbolic acid are mixed together and subjected to heat, a colorless liquid would exist the outcome. The only reference he finds so far with regard to this reaction occurs in the very first-class and valuable scientific publication of Dr. E. R. Squibb, " Ephemeris of Materia Medica", etc., on page 673, vol. ii., No. 5, where a brief allusion appears under the appellation of Compound Alum Pulverisation. Dr. F. R. Squibb, however, in a letter of the alphabet to the writer states that he has " several times before heard of this reaction between phenol and camphor.
  12. ^ Worthen, Dennis (2003). "Edward Robinson Squibb (1819–1900): Advocate of Production Standards". Journal of the American Pharmacists Association. 46 (half-dozen): 754–758. doi:x.1331/1544-3191.46.vi.754.Worthen. PMID 17176693. Archived from the original on 18 April 2014. Retrieved 25 Nov 2014.
  13. ^ Blake, J.B. (1899). "Administration of Ether at the Boston City Hospital". Boston Med Surg J. 141 (13): 312–314. doi:10.1056/NEJM189909281411303. Archived from the original on 27 July 2020. Retrieved 5 July 2019. Until within six months Squibb's other has been exclusively used at the Boston Metropolis Hospital. Recently .MeliiHTéift's ether has been tried, ¡uni has given fair satisfaction ; Squibb'south is yet preferred by most of the firm officers.
  14. ^ Brown, W.South. (1885). "Twoscore Year'southward Feel in Midwifery". Boston Medical and Surgical Journal. 112 (xi): 241. doi:x.1056/nejm188503121121101. Archived from the original on 27 July 2020. Retrieved five July 2019. One reason why ergot has fallen into disrepute is the poor quality of many specimens offered for sale. Dr. Squibb's aqueous extract rarely disappoints me.
  15. ^ Capace, Nancy (1 Jan 2001). Encyclopedia of Delaware. Somerset Publishers, Inc. ISBN978-0-403-09612-one. Archived from the original on fourteen April 2021. Retrieved xv October 2020.
  16. ^ Claire (27 August 2013). "A history of Bristol-Myers Squibb". pharmaphorum.com. Archived from the original on 22 September 2020. Retrieved 1 Baronial 2021.
  17. ^ Smith (2001). Medicines for the Marriage Regular army: the U.s. Ground forces laboratories during the Civil War . Pharmaceutical Products Printing. ISBN9780789009470. Accessed 2014-11-25.
  18. ^ Navy Medicine. Naval Medical Command. 2005. Archived from the original on fourteen April 2021. Retrieved xv Oct 2020.
  19. ^ Rosenbloom, Bert (25 July 2012). Marketing Channels (in German). Cengage Learning. ISBN978-one-133-70757-8. Archived from the original on xiv April 2021. Retrieved xv Oct 2020.
  20. ^ a b c Cox, Jim (xviii September 2008). Sold on Radio: Advertisers in the Golden Age of Broadcasting. McFarland. ISBN978-0-7864-5176-0. Archived from the original on 14 Apr 2021. Retrieved 15 October 2020.
  21. ^ a b Bert Rosenbloom, Marketing Channels, Bristol-Myers Squibb Archived 24 December 2016 at the Wayback Automobile, 2011, folio 609
  22. ^ "Ipana toothpaste tasted success in early 1900s". Loveland Reporter-Herald. 20 April 2017. Archived from the original on 19 October 2021. Retrieved 26 March 2020.
  23. ^ Salpukas, Agis (16 August 1984). "Concern PEOPLE; iii Executive Changes Set up past Bristol-Myers". The New York Times. ISSN 0362-4331. Archived from the original on 26 March 2020. Retrieved 26 March 2020.
  24. ^ Botti, Timothy J. (2006). Envy of the World: A History of the U.S. Economic system & Big Business. Algora Publishing. ISBN978-0-87586-432-vii. Archived from the original on fourteen Apr 2021. Retrieved 15 October 2020.
  25. ^ "Bristol-Myers Squibb marks completion of East Syracuse plant's transformation". syracuse. xiii September 2013. Archived from the original on eleven July 2020. Retrieved 9 July 2020.
  26. ^ "Bristol-Myers Squibb: Big Pharma's small wonder". Fortune. Archived from the original on ten December 2019. Retrieved 10 December 2019.
  27. ^ Harris, Gardiner (19 January 2009). "Drug Making'south Movement Abroad Stirs Concerns". The New York Times. ISSN 0362-4331. Archived from the original on 26 March 2020. Retrieved 26 March 2020.
  28. ^ "At Bristol-Myers Squibb establish in East Syracuse, old buildings volition brand way for new drugs". syracuse. 30 June 2010. Archived from the original on 27 July 2020. Retrieved 28 April 2020.
  29. ^ "Bristol Myers Squibb East Syracuse Pharmaceutical Manufacturing Facility – Pharmaceutical Technology". www.pharmaceutical-technology.com. Archived from the original on 27 July 2020. Retrieved 28 April 2020.
  30. ^ "Bristol-Myers, Squibb Concur to Merge : $12-Billion Stock Swap Would Form second-Largest Drug Business firm". Los Angeles Times. 28 July 1989. Archived from the original on 26 March 2020. Retrieved 26 March 2020.
  31. ^ "NSTMF". NSTMF. Archived from the original on 26 March 2020. Retrieved 26 March 2020.
  32. ^ "Bristol hit with antitrust suit". CNN. four June 2002. Archived from the original on 17 August 2020. Retrieved x July 2013.
  33. ^ a b Chopra, Prem (2009). Masters of the Game. Brook of Life. ISBN978-0-9786321-3-vii. Archived from the original on 14 April 2021. Retrieved xv October 2020.
  34. ^ "Bristol-Myers Squibb Company : Lit. Rel. No. 18822" (Printing release). U.s. Securities and Exchange Commission. half-dozen August 2004. Archived from the original on 21 August 2017. Retrieved ix May 2015. Bristol-Myers inflated its results primarily past: (ane) stuffing its distribution channels with backlog inventory virtually the end of every quarter in amounts sufficient to run across sales and earnings targets set by officers ("channel-stuffing")
  35. ^ "Bristol-Myers to restate earnings as tertiary quarter profits plunge". Archived from the original on v November 2013.
  36. ^ "Bristol-Myers restates results upward due to bookkeeping errors". Archived from the original on 24 September 2015.
  37. ^ Saul, Stephanie (15 June 2005). "2 Sometime Bristol-Myers Executives Charged With Fraud". The New York Times. ISSN 0362-4331. Archived from the original on 11 July 2020. Retrieved 9 July 2020.
  38. ^ a b "Former Bristol-Myers Squibb Senior Executive Pleads Guilty for Role in Quack Dealings with the Federal Government". FBI. Archived from the original on 19 October 2021. Retrieved ix July 2020.
  39. ^ Business Written report Archived 17 August 2007 at the Wayback Machine, July 31, 2006. Retrieved September 7, 2006. Archived at
  40. ^ CNN.com Archived 15 September 2020 at the Wayback Car, September 12, 2006. Retrieved September 12, 2006
  41. ^ a b c d e Wright, Rob (Oct 2018). "From Big to Specialty—The Operational Transformation of Bristol-Myers Squibb". Life Science Leader. Vol. ten, no. 10. Erie, Pennsylvania: VertMarkets. Retrieved 17 October 2018.
  42. ^ "Bristol-Myers Squibb Announces Pension Run a risk Transfer | PLANSPONSOR". world wide web.plansponsor.com. Archived from the original on 27 July 2020. Retrieved 28 Apr 2020.
  43. ^ "Bristol-Myers Squibb Closes United states of america Retirement Plan | Chief Investment Officer". www.ai-cio.com. Archived from the original on 27 July 2020. Retrieved 28 Apr 2020.
  44. ^ a b c Staff (15 February 2015). "BMS CEO Andreotti to Retire; COO named as Successor". Genetic Applied science & Biotechnology News (paper). Vol. 35, no. 4. p. 6.
  45. ^ "A Primer On Biopharma Manufacturing From Bristol-Myers Squibb's Lou Schmukler". world wide web.lifescienceleader.com. Archived from the original on 9 July 2020. Retrieved 9 July 2020.
  46. ^ Herper, Matthew (31 December 2013). "Grading Pharma in 2013". Forbes. Archived from the original on 27 October 2017. Retrieved 25 August 2017.
  47. ^ Anna Edney (22 December 2014). "Bristol-Myers Drug Wins U.S. Approval to Care for Avant-garde Melanoma". Bloomberg. Archived from the original on 31 December 2014. Retrieved five March 2017.
  48. ^ "Bavarian Nordic Could Tally upwardly to $975 One thousand thousand in Prostate Cancer Bargain with BMS – GEN News Highlights – GEN". GEN. 4 March 2015. Archived from the original on 6 March 2015. Retrieved 5 March 2015.
  49. ^ Johnson, Linda A. "New CEO Takes Over Evolving Drugmaker Bristol-Myers Squibb". ABC News. Archived from the original on 7 May 2015. Retrieved 6 May 2015.
  50. ^ "Bristol-Myers Squibb Shares Just Spiked on Reports of a Carl Icahn Stake". Fortune. Archived from the original on 5 August 2017. Retrieved 23 May 2017.
  51. ^ Benoit, David; Rockoff, Jonathan D. (22 Feb 2017). "Carl Icahn Takes Pale in Bristol-Myers Squibb". The Wall Street Periodical. Archived from the original on 22 May 2017. Retrieved 23 May 2017.
  52. ^ "Making (good) deals is hard to do, Gilead CEO says, but he'due south working on information technology – FiercePharma". fiercepharma.com. Archived from the original on 10 June 2017. Retrieved 23 May 2017.
  53. ^ LaVito, Angelica (26 April 2018). "Bristol-Myers' cancer drug Opdivo fuels growth, only revenue falls short". CNBC. Archived from the original on eleven December 2019. Retrieved 11 December 2019.
  54. ^ https://finance.yahoo.com/news/BristolMyers-Squibb-to-bw-571310065.html?x=0&.v=1 [ permanent dead link ]
  55. ^ "Bristol-Myers to Buy Medarex For $2.four Billion". 23 July 2009. Archived from the original on 14 April 2021. Retrieved 5 December 2020.
  56. ^ a b Woelfel, Joseph. "Bristol-Myers to Split up Off Mead Johnson". TheStreet. Archived from the original on 10 July 2020. Retrieved 9 July 2020.
  57. ^ "Bristol Buys Inhibitex for $2.v Billion to Compete in Hepatitis". 8 January 2012. [ permanent dead link ]
  58. ^ a b Gershberg, Michele (30 June 2012). "Bristol-Myers to buy Amylin for about Usa$five.iii billion". Reuters. Archived from the original on 9 August 2020. Retrieved v July 2021.
  59. ^ "Bristol-Myers buy Inhibitex". Bristol-Myers Squibb . Retrieved 29 Nov 2021.
  60. ^ "GEN – News Highlights:BMS Deals Add to its Immuno-Oncology Portfolio". GEN. 23 February 2015. Archived from the original on 24 Feb 2015. Retrieved 24 February 2015.
  61. ^ "BMS to Buy Cardioxyl for Up to $two.075B". GEN. two November 2015. Archived from the original on 4 March 2016. Retrieved 2 November 2015.
  62. ^ "BMS to Acquire Padlock Therapeutics for Upwards to $600M". GEN. 23 March 2016. Archived from the original on half dozen September 2017. Retrieved 23 March 2016.
  63. ^ "BMS Snags Cormorant Pharmaceuticals for Upward to $520M (online title: BMS Acquires Cormorant Pharmaceuticals for Up to $520M)". News: Manufacture Watch (online: GEN News Highlights). Genetic Applied science & Biotechnology News. 36 (14): x. August 2016. Archived from the original on ten July 2017. Retrieved 5 July 2016.
  64. ^ Reuters Editorial (3 August 2017). "Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline". Reuters. Archived from the original on 5 Baronial 2017. Retrieved v Baronial 2017.
  65. ^ "Celgene, Bristol-Myers prepare $two.2 billion termination fee for their mega deal". Reuters. 4 January 2019. Archived from the original on 28 April 2021. Retrieved 19 October 2021 – via www.reuters.com.
  66. ^ a b Spalding, Rebecca; Koons, Cynthia (3 January 2019). "Bristol Myers Squibb To Buy Celgene In $74 Billion Cancer-Drug Bet". www.bloomberg.com. Archived from the original on 3 Jan 2019. Retrieved three January 2019.
  67. ^ a b Herbst-Bayliss, Svea; Erman, Michael (28 February 2019). "Starboard joins opposition to Bristol-Myers' $74 billion Celgene bargain". Reuters. Archived from the original on 28 February 2019. Retrieved 3 March 2019. Starboard reported on Thursday that it at present owns iv.4 million shares, or 0.three pct of Bristol'south outstanding shares, while Wellington owns an eight pct stake.
  68. ^ Bristol-Myers Squibb Shareholders Approve Celgene Acquisition Archived 10 May 2019 at the Wayback Motorcar, PM BMS April 12, 2019, retrieved May 13, 2019
  69. ^ "Bristol-Myers Squibb completes acquisition of Celgene". European Pharmaceutical Review. 22 Nov 2019. Archived from the original on 11 December 2019. Retrieved 11 December 2019.
  70. ^ "Bristol-Myers Squibb completes divestment of consumer health business, UPSA to Taisho Pharma". Pharmabiz.com (Churnalism). Republic of india: Saffron Media. two July 2019. Archived from the original on 27 July 2020. Retrieved 4 July 2019.
  71. ^ a b "Excedrin brand for sale". News > Fortune 500. CNN Money. Reuters. 12 Jan 2005. Archived from the original on 16 April 2021. Retrieved 3 Baronial 2020.
  72. ^ a b "Bristol-Myers Squibb to Divest Three Consumer Brands" (Printing release). Bristol-Myers Squibb Company. 21 September 1998. Archived from the original on 4 March 2016 – via PRNewswire.
  73. ^ a b "Bristol-Myers Squibb Plans To Divest U.S. And Canadian Consumer Medicines Concern" (Press release). Bristol-Myers Squibb. 12 January 2005. Archived from the original on 3 March 2016. Retrieved 25 February 2016 – via BusinessWire.
  74. ^ "Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Cyberspace Of Anticipated Future Cash Tax Benefits". BioSpace. Archived from the original on xix October 2021. Retrieved 19 October 2021.
  75. ^ "Amgen to buy Celgene psoriasis drug Otezla for $13.four billion". Reuters. 26 August 2019. Archived from the original on xxx April 2021. Retrieved nineteen October 2021 – via www.reuters.com.
  76. ^ "Bristol-Myers launches biotech targeting fibrosis, inflammation". BioPharma Dive. Archived from the original on 3 March 2020. Retrieved 3 March 2020.
  77. ^ "Bristol Myers Squibb Enters Agreement to Larn Forbius, Adding Pb TGF-beta Asset to Portfolio". BioSpace. Archived from the original on 19 October 2021. Retrieved 19 Oct 2021.
  78. ^ "BMS Strengthens Cardiovascular Business organisation with $13.1 Billion MyoKardia Buyout". Biospace. 5 October 2020. Archived from the original on eleven October 2020. Retrieved 18 November 2020.
  79. ^ "Bristol-Myers Squibb Acquirement 2006–2018 | BMY". macrotrends.net. Archived from the original on ane November 2018. Retrieved 31 October 2018.
  80. ^ "Bristol-Myers Squibb: Diversity and calibration in biopharma". DHL. June 2019. Archived from the original on 11 December 2019. Retrieved xi December 2019.
  81. ^ "What Per centum Does Bristol-Myers Squibb Spend On R&D, 30%, 40%, Or l%?". Forbes. 28 November 2019. Archived from the original on eleven December 2019. Retrieved 11 December 2019.
  82. ^ "Bristol-Myers Squibb". Fortune. Archived from the original on 21 Nov 2018. Retrieved 20 November 2018.
  83. ^ "Bristol Myers Squibb's Sustainability Report for 2020Q4" (PDF). Archived from the original (PDF) on x October 2021. Alt URL
  84. ^ "Bristol Myers Squibb'south Sustainability Report for 2020Q4" (PDF). Archived from the original (PDF) on ten October 2021. [Climate%20Goal,Total%20CO2e%20emissions%20(Scope%201%20%2b%20Scope%202)/2020Q4 Alt URL]
  85. ^ "Bristol Myers Squibb'due south Sustainability Report for 2020Q4" (PDF). Archived from the original (PDF) on 10 Oct 2021. Alt URL
  86. ^ "Selected Products of Bristol-Myers Squibb". © 2015 Bristol-Myers Squibb Company. Archived from the original on iv May 2017. Retrieved thirty May 2015.
  87. ^ Johnson DB, Peng C, Sosman JA (2015). "Nivolumab in melanoma: latest prove and clinical potential". Ther Adv Med Oncol. vii (ii): 97–106. doi:10.1177/1758834014567469. PMC4346215. PMID 25755682.
  88. ^ "Generic Taxol Availability". drugs.com. Archived from the original on 30 April 2016. Retrieved 23 January 2018.
  89. ^ "Bristol-Myers Squibb: the Pipeline". © 2015 Bristol-Myers Squibb Company. Archived from the original on 12 May 2015. Retrieved 30 May 2015.
  90. ^ "Johns Hopkins, Bristol-Myers must face $one billion syphilis infections conform". Reuters. Archived from the original on 18 January 2021. Retrieved 27 March 2020.
  91. ^ Mariani, Mike (28 May 2015). "The Guatemala Experiments". Pacific Standard. The Miller-McCune Heart for Research, Media and Public Policy. Archived from the original on ten February 2020. Retrieved vii January 2015.

External links [edit]

  • Official website
  • Bristol-Myers Squibb worldwide locations
  • Business information for Bristol Myers Squibb:
    • Google Finance
    • Yahoo! Finance
    • SEC filings
  • Bristol-Myers Squibb Influence and Lobbying Summary – Opensecrets.org

ethertonalianobson1961.blogspot.com

Source: https://en.wikipedia.org/wiki/Bristol_Myers_Squibb

Post a Comment for "what tree does the drug company bristol-myers want to harvest?"